Palbociclib in Older Patients with Advanced/Metastatic Breast Cancer: A Systematic Review.

ABSTRACT:

Background

Palbociclib in combination with endocrine therapy is approved for treatment of hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer. In addition to clinical trials, several real-world studies have evaluated the effectiveness of palbociclib. With increased life expectancy in the general population, breast cancer in older women is also expected to increase.

Objective

The aim was to systematically review evidence from both clinical trials and real-world studies for palbociclib treatment outcomes in older patients with HR+/HER2- advanced/metastatic breast cancer (a/mBC). Older patients are often underrepresented in clinical trials, and real-world evidence (RWE) will enrich the analysis of palbociclib outcomes

SUBMITTER: Brain E 

PROVIDER: S-EPMC11111485 | biostudies-literature | 2024 May

REPOSITORIES: biostudies-literature